Alumis Shares Soar 250% in a Year, Yet BML Capital Cashes Out $5 Million Stake
As clinical-stage biotech Alumis sees its stock price skyrocket on optimism for its autoimmune disease pipeline, one investment fund has made a contrarian move, selling its entire position just before a major rally.